Background: Our previous study indicated that emergency contraception, including levonorgestrel and progesterone, could lead to ectopic pregnancy following contraception failure. However, our understanding of the effects of levonorgestrel and progesterone on oviductal physiology is limited.
Methods: The receptivity of the fallopian tubal epithelium after levonorgestrel and progesterone treatment was examined through western blots for receptivity markers and JAr-spheroid-fallopian tubal epithelial cell attachment assays. The ciliary beat frequency was analyzed using an inverted bright-field microscope. Furthermore, an in vivo animal model of embryo-tubal transplantation was also studied to determine the effects of levonorgestrel- and progesterone-induced ciliary beat reduction.
Results: Our results showed that levonorgestrel and progesterone did not change the levels of fallopian tubal epithelial cell receptive markers, including LIF, STAT3, IGFBP1, ITGB3, MUC1, and ACVR1B, or affect JAr-spheroid implantation. However, levonorgestrel and progesterone reduced the ciliary beat frequency in fallopian tubes in a dose-dependent manner. An in vivo model also showed that levonorgestrel and progesterone could lead to embryo retention in the oviducts.
Conclusions: These findings show that levonorgestrel and progesterone can reduce the ciliary beat frequency without altering receptivity, indicating a possible mechanism for progesterone- or levonorgestrel-induced tubal pregnancy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011509 | PMC |
| http://dx.doi.org/10.1186/s12958-018-0377-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS).
Sci Rep
January 2025
Department of pharmacy, Heze University, Heze, 274000, Shandong Province, China.
Progestogens commonly used in the clinic include levonorgestrel, etonogestrel, medroxyprogesterone, hydroxyprogesterone, progesterone, desogestrel, and megestrol. Progestogens are widely used for contraception and the treatment of endometriosis, threatened abortion and other diseases. However, the correlation between progestogen use and depression is not clear.
View Article and Find Full Text PDFState of the art endocrine treatments for patients diagnosed with endometrial cancer in 2025.
Curr Opin Obstet Gynecol
December 2024
Mount Sinai Medical Center, Miami Beach, Florida, USA.
Purpose Of Review: Endometrial cancer (EC) is rising in incidence, particularly in younger, premenopausal women, due to increasing rates of obesity and delayed childbearing. This review evaluates current and emerging endocrine therapies, with a focus on fertility-preserving approaches for early-stage EC and treatment options for advanced or recurrent disease.
Recent Findings: Fertility-sparing endocrine therapies, such as medroxyprogesterone acetate, megestrol acetate, and levonorgestrel-releasing intrauterine devices, achieve high response rates but carry recurrence risks.
Cost-effectiveness of long-acting progestogens versus the combined oral contraceptives pill for preventing recurrence of endometriosis-related pain following surgery: an economic evaluation alongside the PRE-EMPT trial.
BMJ Open
December 2024
Health Economics Unit, Department of Applied Health Science, College of Medicine and Health, University of Birmingham, Birmingham, B15 2TT, UK
Objectives: To evaluate the cost-effectiveness of long-acting progestogens (LAP), including levonorgestrel-releasing intrauterine system (LNG-IUS) and depot-medroxyprogesterone acetate (DMPA), compared with the combined oral contraceptives pill (COCP) in preventing recurrence of endometriosis-related pain postsurgery.
Design: Within-trial economic evaluation alongside a multicentre, pragmatic, parallel-group, open-label, randomised controlled trial (Preventing Recurrence of Endometriosis by means of Long-Acting Progestogen Therapy trial).
Setting: Thirty-four UK hospitals recruiting participants from November 2015 to March 2019.
Levonorgestrel at emergency contraception dose has no effect on ciliary beat frequency and muscular contraction of the human fallopian tube: an in vitro experimental study.
Reprod Biol Endocrinol
November 2024
Department of Obstetrics and Gynaecology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 102 Pokfulam Road, Pok Fu Lam, Hong Kong.
Article Synopsis
- Levonorgestrel (LNG) is primarily used as an emergency contraceptive by delaying ovulation, and this study aimed to explore its effects on the human Fallopian tube's ciliary movement and muscle contractions.
- In an experimental setup using tissue samples from women, the researchers tested LNG at various concentrations to see any changes in ciliary beat frequency and muscular contractions.
- Results showed that while LNG did not significantly affect ciliary movement or muscle tone, the highest concentration (100 ng/ml) did reduce muscular contractions, indicating that the Fallopian tube is not likely a target for LNG's contraceptive effects at typical emergency contraception doses.
Endometrial Proliferation and Heavy Menstrual Bleeding Associated With Continuous Oral Contraceptive Use.
Cureus
October 2024
Obstetrics and Gynecology, New Tampa OBGYN, Tampa, USA.
Continuous oral contraceptives are intended for three months of levonorgestrel/ethinylestradiol use followed by 10 days of low-dose ethinylestradiol. When taken for extended periods without withdrawal bleeds, side effects may include heavy menstrual bleeding and endometrial proliferation. A 41-year-old female presented to the OB-GYN clinic with two months of heavy menstrual bleeding after 10 years of Seasonique use without withdrawal bleeds (10 days of low-dose ethinylestradiol).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!